S. Cattan

539 total citations
17 papers, 425 citations indexed

About

S. Cattan is a scholar working on Oncology, Epidemiology and Hepatology. According to data from OpenAlex, S. Cattan has authored 17 papers receiving a total of 425 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Oncology, 6 papers in Epidemiology and 6 papers in Hepatology. Recurrent topics in S. Cattan's work include Hepatocellular Carcinoma Treatment and Prognosis (5 papers), Colorectal Cancer Treatments and Studies (4 papers) and Pancreatic and Hepatic Oncology Research (4 papers). S. Cattan is often cited by papers focused on Hepatocellular Carcinoma Treatment and Prognosis (5 papers), Colorectal Cancer Treatments and Studies (4 papers) and Pancreatic and Hepatic Oncology Research (4 papers). S. Cattan collaborates with scholars based in France, United States and Italy. S. Cattan's co-authors include Jean–Pierre Gendre, Jacques Cosnes, Franck Carbonnel, Laurent Beaugerie, Antoine Blain, Géraldine Sergent, Pascal Hammel, Abbas Mourad, Emmanuel Boleslawski and F.-R. Pruvot and has published in prestigious journals such as Journal of Clinical Oncology, Gut and Journal of Hepatology.

In The Last Decade

S. Cattan

15 papers receiving 418 citations

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
S. Cattan 215 148 137 124 121 17 425
Víctor Sapena 228 1.1× 50 0.3× 75 0.5× 222 1.8× 74 0.6× 35 422
Mohamad Mouchli 53 0.2× 81 0.5× 130 0.9× 99 0.8× 130 1.1× 39 366
Eun Hye Oh 222 1.0× 226 1.5× 94 0.7× 26 0.2× 163 1.3× 54 466
Pieter‐Jan Cuyle 102 0.5× 93 0.6× 146 1.1× 16 0.1× 106 0.9× 22 345
Michèle D. Bishop 73 0.3× 53 0.4× 87 0.6× 40 0.3× 150 1.2× 8 317
Masato Ueno 60 0.3× 62 0.4× 97 0.7× 26 0.2× 147 1.2× 38 463
Melanie Langheinrich 58 0.3× 43 0.3× 150 1.1× 43 0.3× 149 1.2× 34 392
Giorgina Mieli-Vergani 304 1.4× 56 0.4× 47 0.3× 368 3.0× 154 1.3× 14 549
Richard Knoop 161 0.7× 22 0.1× 139 1.0× 55 0.4× 78 0.6× 26 302
Donghong Lu 129 0.6× 22 0.1× 48 0.4× 75 0.6× 33 0.3× 17 340

Countries citing papers authored by S. Cattan

Since Specialization
Citations

This map shows the geographic impact of S. Cattan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by S. Cattan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites S. Cattan more than expected).

Fields of papers citing papers by S. Cattan

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by S. Cattan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by S. Cattan. The network helps show where S. Cattan may publish in the future.

Co-authorship network of co-authors of S. Cattan

This figure shows the co-authorship network connecting the top 25 collaborators of S. Cattan. A scholar is included among the top collaborators of S. Cattan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with S. Cattan. S. Cattan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Laethem, J-L. van, Ivan Borbath, Mark Karwal, et al.. (2021). 933P Updated results for pembrolizumab (pembro) monotherapy as first-line therapy for advanced hepatocellular carcinoma (HCC) in the phase II KEYNOTE-224 study. Annals of Oncology. 32. S819–S819. 1 indexed citations
2.
Kelley, Robin Kate, Anthony B. El-Khoueiry, Tim Meyer, et al.. (2018). Outcomes by baseline alpha-fetoprotein (AFP) levels in the phase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in previously treated advanced hepatocellular carcinoma (HCC). Annals of Oncology. 29. viii236–viii236. 9 indexed citations
3.
4.
Hollebecque, Antoine, S. Cattan, Géraldine Sergent, et al.. (2011). Safety and efficacy of sorafenib in hepatocellular carcinoma: the impact of the Child-Pugh score. Alimentary Pharmacology & Therapeutics. 34(10). 1193–1201. 89 indexed citations
5.
Levy, Gary, S. Cattan, Géraldine Sergent, et al.. (2011). 626 ASSESSMENT OF RESPONSE TO SORAFENIB IN HEPATOCELLULAR CARCINOMA: PROGNOSTIC VALUE OF TUMORAL DENSITY AND ARTERIAL ENHANCEMENT MEASUREMENTS IN TARGET LESIONS. Journal of Hepatology. 54. S254–S254. 1 indexed citations
6.
7.
Cattan, S., Sébastien Dharancy, V. Canva, et al.. (2009). 66 PROSPECTIVE EVALUATION OF SORAFENIB (SO) IN PATIENTS WITH HEPATOCELLULAR CARCINOMA (HCC): DOES CHILD SCORE B INFLUENCE SAFETY?. Journal of Hepatology. 50. S28–S28. 1 indexed citations
8.
Cattan, S., Mohamed Hebbar, Sébastien Dharancy, et al.. (2009). CO.46 Fréquence et prise en charge thérapeutique de la toxicité cutanée du sorafenib dans le carcinome hépatocellulaire. Gastroentérologie Clinique et Biologique. 33(3). A120–A120. 1 indexed citations
9.
Christophe, Véronique, et al.. (2009). Quelle perception les praticiens ont-ils de l'annonce de mauvaises nouvelles en oncologie ? Analyse qualitative du vécu et des stratégies de régulation émotionnelle What is the physicians' perception on giving bad news in oncology? Qualitative analysis of the emotional experience and emotional regulation strategies.
10.
11.
Flesch, M., Mohammed Bennamoun, Françoise Galateau-Sallé, et al.. (2004). Multicentric phase II study of epirubicin and docetaxel as first line treatment for patients with advanced gastric cancer: A GERCOR study. Journal of Clinical Oncology. 22(14_suppl). 4062–4062. 1 indexed citations
12.
Cattan, S.. (2004). Entendre l’annonce du cancer. Éthique & Santé. 1(3). 116–119. 2 indexed citations
13.
Blain, Antoine, S. Cattan, Laurent Beaugerie, et al.. (2002). Crohn's disease clinical course and severity in obese patients. Clinical Nutrition. 21(1). 51–57. 186 indexed citations
14.
Louvet, Christophe, Thierry André, Pascal Hammel, et al.. (2001). Phase II trial of bimonthly leucovorin, 5-fluorouracil and gemcitabine for advanced pancreatic adenocarcinoma (FOLFUGEM). Annals of Oncology. 12(5). 675–679. 33 indexed citations
15.
Cattan, S., Dominique Wendum, Olivier Chazouillères, Jacques Schmitz, & Jean–Pierre Gendre. (2000). Hepatocellular carcinoma and focal hepatic glycogenosis after prolonged azathioprine therapy. Human Pathology. 31(7). 874–876. 26 indexed citations
16.
Sézeur, A, Armand de Gramont, E. Touboul, et al.. (1999). [Contribution of telemedicine applied to digestive cancer].. PubMed. 23(3). 342–7. 4 indexed citations
17.
Raynaud, Alain, et al.. (1982). A propos d'un cas d'adénome parathyroïdien médiastinal traité par embolisation. La Revue de Médecine Interne. 3(2). 147–152.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Víctor Sapena Breakdown of academic impact, for papers by Mohamad Mouchli Breakdown of academic impact, for papers by Eun Hye Oh Breakdown of academic impact, for papers by Pieter‐Jan Cuyle Breakdown of academic impact, for papers by Michèle D. Bishop Breakdown of academic impact, for papers by Masato Ueno Breakdown of academic impact, for papers by Melanie Langheinrich Breakdown of academic impact, for papers by Giorgina Mieli-Vergani Breakdown of academic impact, for papers by Richard Knoop Breakdown of academic impact, for papers by Donghong Lu
Rankless by CCL
2026